Clinical effect of alirocumab combined with simvastatin on treatment of patients with acute ST-segment elevation myocardial infarction
Sun Jingyu
Hao Liuyi
Guo Zhouwei
Abstract：Objective To observe the clinical effect of alirocumab combined with simvastatin on treatment of the patients with acute ST-segment elevation myocardial infarction(STEMI)so as to propose a novel and innovative treatment strategy for this dis-ease.Methods A total of 129 patients with acute STEMI who were admitted to Yuncheng Central Hospital,Shanxi Medical Uni-versity from May 2023 to November 2024 were enrolled in the study and randomly divided into three groups using a random number table:the simvastatin group(SG),the alirocumab group(AG),and the combined treatment group(CG),with 43 patients in each group.The SG received conventional treatment with oral simvastatin tablets at a dose of 40 mg once daily in the evening.The AG group received conventional treatment with subcutaneous injections of alirocumab at a dose of 75 mg every 2 weeks.The CG group received conventional treatment with both simvastatin tablets and alirocumab injections.The treatment course was 2 weeks,and the total duration was 4 weeks.The clinical efficacy observed and compared after four weeks of treatment,while the changes in the lev-els of myoglobin(Mb),cardiac troponin(cTnT),creatine kinase isoenzyme(CK-MB),hypersensitive C-responsive protein(hs-CRP),TNF-α,inter-cell-cell adhesion molecule-1(ICAM-1),total cholesterol(TC),triglycerides(TG),high-density lipoprotein cholesterol(HDL-C),LDL-C,and cardiovascular events(MACE)were compared.Results The total effective rate was 62.79%(27/43)in the SG group,53.49%(23/43)in the AG group,86.05%(37/43)in the CG group,significantly higher than those in the SG group(χ2=6.108,P=0.013)and the AG group(χ2=10.805,P<0.05),and there was no significant difference in the total effective rate between the SG group and the AG group(χ2=0.764,P=0.382).The levels of Mb,CK-MB,cTnT,hs-CRP,TNF-α and ICAM-1 were lower in the CG group than in the SG group after the treatment(t=-9.327,7.730,4.006,9.675,2.497,10.912,all P<0.05)and the AG group(t=10.483,9.791,4.800,8.871,4.135,10.851,all P<0.05).After treatment,the levels of TC,TG,LDL-C were remarkably lower in the CG group than in the SG group(t=8.323,8.786,12.693,all P<0.05)and the AG group(t=7.629,8.437,11.032,all P<0.05).and the level of HDL-C was significantly higher than the SG group(t=-5.747,P<0.05)and the AG group(t=-5.612,P<0.05);The inci-dence of MACE was 13.95%(6/43)in the SG group,20.93%(9/43)in the AG group,no MACE in the CG group,and the incidence of MACE was significantly lower in the CG group than in the SG group(χ2=4.479,P<0.05)and the AG group(χ2=7.942,P<0.05).The incidence of adverse reactions was 23.26%(10/43)in the CG group,27.91%(12/43)in the SG group and 20.93%(9/43)in the AG group.There was no statistically significant difference among the three groups(χ2=0.595,P>0.05).Conclusion The combina-tion of alirocumab and simvastatin for the treatment of acute STEMI is highly effective,with a low incidence of MACE and adverse reactions.
Keywords：Acute ST-segment elevation myocardial infarctionAlirocumabSimvastatinEfficacy observation
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 411-415 )